Boston Scientific Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Boston Scientific

BSX 100.89

+0.6%

2:59 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Tom Caruthers	6/18/2008 9:38:53 AM
	Read Replies (1) of 20

Just bought in to BSX today in the $13.60's. Abbott has their Xience stent that should be approved in June sometime. BSX, through their acquisition of Guidant, has co-marketing rights to sell a white labelled version of the stent called Promus, though will have to pay 40% royalties to Abbott. Was debating whether to buy Abbott or BSX. Abbott is too large that even a $1-2B device doesn't move the dial very much. For BSX, however, it means a lot. The one caveat is whether or not Promus will cannibalize Taxus sales. But it would happen one way or the other and at least this way, they can offset the market share loss. The stock has been basing since early May and the chart looks very constructive. Good luck and don't say I didn't tell you! Tom

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next